journal
Journals Annual Review of Pharmacology ...

Annual Review of Pharmacology and Toxicology

https://read.qxmd.com/read/38261428/alcohol-use-disorder-treatment-problems-and-solutions
#1
REVIEW
George F Koob
Alcohol use disorder (AUD) afflicts over 29 million individuals and causes more than 140,000 deaths annually in the United States. A heuristic framework for AUD includes a three-stage cycle-binge/intoxication, withdrawal/negative affect, and preoccupation/anticipation-that provides a starting point for exploring the heterogeneity of AUD with regard to treatment. Effective behavioral health treatments and US Food and Drug Administration-approved medications are available but greatly underutilized, creating a major treatment gap...
January 23, 2024: Annual Review of Pharmacology and Toxicology
https://read.qxmd.com/read/37816308/introduction-to-the-theme-pharmacological-individuality-new-insights-and-strategies-for-personalized-and-precise-drug-treatment
#2
REVIEW
Urs A Meyer, Susan G Amara, Terrence F Blaschke, Paul A Insel
The reviews in Volume 64 of the Annual Review of Pharmacology and Toxicology cover diverse topics. A common theme in many of the reviews is the interindividual variability in the clinical response to drugs. Highlighted areas include emerging developments in pharmacogenomics that can predict the personal risk for drug inefficacy and/or adverse drug reactions. Other reviews focus on the use of circulating biomarkers to define drug metabolism phenotypes and the effect of circadian regulation on drug response. Another emerging technology, digital twins that model individual patients, is used to generate computational simulations of drug effects and identify optimal personalized treatments...
January 23, 2024: Annual Review of Pharmacology and Toxicology
https://read.qxmd.com/read/37788493/antiepileptic-drugs-as-potential-dementia-prophylactics-following-traumatic-brain-injury
#3
REVIEW
Laszlo F Locskai, Hadeel Alyenbaawi, W Ted Allison
Seizures and other forms of neurovolatility are emerging as druggable prodromal mechanisms that link traumatic brain injury (TBI) to the progression of later dementias. TBI neurotrauma has both acute and long-term impacts on health, and TBI is a leading risk factor for dementias, including chronic traumatic encephalopathy and Alzheimer's disease. Treatment of TBI already considers acute management of posttraumatic seizures and epilepsy, and impressive efforts have optimized regimens of antiepileptic drugs (AEDs) toward that goal...
January 23, 2024: Annual Review of Pharmacology and Toxicology
https://read.qxmd.com/read/37758192/oral-anticoagulants-beyond-warfarin
#4
REVIEW
Renske H Olie, Kristien Winckers, Bianca Rocca, Hugo Ten Cate
Direct oral anticoagulants (DOACs) have largely replaced vitamin K antagonists, mostly warfarin, for the main indications for oral anticoagulation, prevention and treatment of venous thromboembolism, and prevention of embolic stroke in atrial fibrillation. While DOACs offer practical, fixed-dose anticoagulation in many patients, specific restrictions or contraindications may apply. DOACs are not sufficiently effective in high-thrombotic risk conditions such as antiphospholipid syndrome and mechanical heart valves...
January 23, 2024: Annual Review of Pharmacology and Toxicology
https://read.qxmd.com/read/37722720/circadian-regulation-of-drug-responses-toward-sex-specific-and-personalized-chronotherapy
#5
REVIEW
Francis A Lévi, Alper Okyar, Eva Hadadi, Pasquale F Innominato, Annabelle Ballesta
Today's challenge for precision medicine involves the integration of the impact of molecular clocks on drug pharmacokinetics, toxicity, and efficacy toward personalized chronotherapy. Meaningful improvements of tolerability and/or efficacy of medications through proper administration timing have been confirmed over the past decade for immunotherapy and chemotherapy against cancer, as well as for commonly used pharmacological agents in cardiovascular, metabolic, inflammatory, and neurological conditions. Experimental and human studies have recently revealed sexually dimorphic circadian drug responses...
January 23, 2024: Annual Review of Pharmacology and Toxicology
https://read.qxmd.com/read/37585661/the-nocebo-effect
#6
REVIEW
Luana Colloca
Adverse nocebo responses can cause harm to patients and interfere with treatment adherence and effects in both clinic practice and clinical trials. Nocebo responses refer to negative outcomes to active medical treatments in clinical trials or practice that cannot be explained by the treatment's pharmacologic effects. Negative expectancies and nocebo effects are less known than placebo responses. Nocebo effects can be triggered by verbal suggestions, prior negative experiences, observation of others experiencing negative outcomes, and other contextual and environmental factors...
January 23, 2024: Annual Review of Pharmacology and Toxicology
https://read.qxmd.com/read/37788492/anthracycline-toxicity-light-at-the-end-of-the-tunnel
#7
REVIEW
Romina B Cejas, Kateryna Petrykey, Yadav Sapkota, Paul W Burridge
Anthracycline-induced cardiotoxicity (AIC) is a serious and common side effect of anthracycline therapy. Identification of genes and genetic variants associated with AIC risk has clinical potential as a cardiotoxicity predictive tool and to allow the development of personalized therapies. In this review, we provide an overview of the function of known AIC genes identified by association studies and categorize them based on their mechanistic implication in AIC. We also discuss the importance of functional validation of AIC-associated variants in human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) to advance the implementation of genetic predictive biomarkers...
October 3, 2023: Annual Review of Pharmacology and Toxicology
https://read.qxmd.com/read/37788491/gene-environment-interactions-my-unique-journey
#8
REVIEW
Daniel W Nebert
I am deeply honored to be invited to write this scientific autobiography. As a physician-scientist, pediatrician, molecular biologist, and geneticist, I have authored/coauthored more than 600 publications in the fields of clinical medicine, biochemistry, biophysics, pharmacology, drug metabolism, toxicology, molecular biology, cancer, standardized gene nomenclature, developmental toxicology and teratogenesis, mouse genetics, human genetics, and evolutionary genomics. Looking back, I think my career can be divided into four distinct research areas, which I summarize mostly chronologically in this article: ( a ) discovery and characterization of the AHR/CYP1 axis, ( b ) pharmacogenomics and genetic prediction of response to drugs and other environmental toxicants, ( c ) standardized drug-metabolizing gene nomenclature based on evolutionary divergence, and ( d ) discovery and characterization of the SLC39A8 gene encoding the ZIP8 metal cation influx transporter...
October 3, 2023: Annual Review of Pharmacology and Toxicology
https://read.qxmd.com/read/37738505/artificial-intelligence-for-drug-discovery-are-we-there-yet
#9
REVIEW
Catrin Hasselgren, Tudor I Oprea
Drug discovery is adapting to novel technologies such as data science, informatics, and artificial intelligence (AI) to accelerate effective treatment development while reducing costs and animal experiments. AI is transforming drug discovery, as indicated by increasing interest from investors, industrial and academic scientists, and legislators. Successful drug discovery requires optimizing properties related to pharmacodynamics, pharmacokinetics, and clinical outcomes. This review discusses the use of AI in the three pillars of drug discovery: diseases, targets, and therapeutic modalities, with a focus on small-molecule drugs...
September 22, 2023: Annual Review of Pharmacology and Toxicology
https://read.qxmd.com/read/37738504/mass-spectrometry-based-proteogenomics-new-therapeutic-opportunities-for-precision-medicine
#10
REVIEW
Sunil K Joshi, Paul Piehowski, Tao Liu, Sara J C Gosline, Jason E McDermott, Brian J Druker, Elie Traer, Jeffrey W Tyner, Anupriya Agarwal, Cristina E Tognon, Karin D Rodland
Proteogenomics refers to the integration of comprehensive genomic, transcriptomic, and proteomic measurements from the same samples with the goal of fully understanding the regulatory processes converting genotypes to phenotypes, often with an emphasis on gaining a deeper understanding of disease processes. Although specific genetic mutations have long been known to drive the development of multiple cancers, gene mutations alone do not always predict prognosis or response to targeted therapy. The benefit of proteogenomics research is that information obtained from proteins and their corresponding pathways provides insight into therapeutic targets that can complement genomic information by providing an additional dimension regarding the underlying mechanisms and pathophysiology of tumors...
September 22, 2023: Annual Review of Pharmacology and Toxicology
https://read.qxmd.com/read/37722722/novel-immunopharmacological-drugs-for-the-treatment-of-allergic-diseases
#11
REVIEW
Ekaterini Tiligada, Daria Gafarov, Maria Zaimi, Joana Vitte, Francesca Levi-Schaffer
The exponential rise in the prevalence of allergic diseases since the mid-twentieth century has led to a genuine public health emergency and has also fostered major progress in research on the underlying mechanisms and potential treatments. The management of allergic diseases benefits from the biological revolution, with an array of novel immunomodulatory therapeutic and investigational tools targeting players of allergic inflammation at distinct pathophysiological steps. Prominent examples include therapeutic monoclonal antibodies against cytokines, alarmins, and their receptors, as well as small-molecule modifiers of signal transduction mainly mediated by Janus kinases and Bruton's tyrosine kinases...
September 18, 2023: Annual Review of Pharmacology and Toxicology
https://read.qxmd.com/read/37722721/deciphering-drug-targets-and-actions-with-single-cell-and-spatial-resolution
#12
REVIEW
Zhengyuan Pang, Benjamin F Cravatt, Li Ye
Recent advances in chemical, molecular, and genetic approaches have provided us with an unprecedented capacity to identify drug-target interactions across the whole proteome and genome. Meanwhile, rapid developments of single-cell and spatial omics technologies are revolutionizing our understanding of the molecular architecture of biological systems. However, a significant gap remains in how we align our understanding of drug actions, traditionally based on molecular affinities, with the in vivo cellular and spatial tissue heterogeneity revealed by these newer techniques...
September 18, 2023: Annual Review of Pharmacology and Toxicology
https://read.qxmd.com/read/37708433/orexin-receptor-antagonism-normalizing-sleep-architecture-in-old-age-and-disease
#13
REVIEW
Jarrah O-Z J Kron, Ryan J Keenan, Daniel Hoyer, Laura H Jacobson
Sleep is essential for human well-being, yet the quality and quantity of sleep reduce as age advances. Older persons (>65 years old) are more at risk of disorders accompanied and/or exacerbated by poor sleep. Furthermore, evidence supports a bidirectional relationship between disrupted sleep and Alzheimer's disease (AD) or related dementias. Orexin/hypocretin neuropeptides stabilize wakefulness, and several orexin receptor antagonists (ORAs) are approved for the treatment of insomnia in adults. Dysregulation of the orexin system occurs in aging and AD, positioning ORAs as advantageous for these populations...
September 14, 2023: Annual Review of Pharmacology and Toxicology
https://read.qxmd.com/read/37708432/translational-in-vivo-assays-in-behavioral-biology
#14
REVIEW
Sarah L Withey, Diego A Pizzagalli, Jack Bergman
The failure of preclinical research to advance successful candidate medications in psychiatry has created a paradigmatic crisis in psychiatry. The Research Domain Criteria (RDoC) initiative was designed to remedy this situation with a neuroscience-based approach that employs multimodal and cross-species in vivo methodology to increase the probability of translational findings and, consequently, drug discovery. The present review underscores the feasibility of this methodological approach by briefly reviewing, first, the use of multidimensional and cross-species methodologies in traditional behavioral pharmacology and, subsequently, the utility of this approach in contemporary neuroimaging and electrophysiology research-with a focus on the value of functionally homologous studies in nonhuman and human subjects...
September 14, 2023: Annual Review of Pharmacology and Toxicology
https://read.qxmd.com/read/37708431/molecular-activation-of-nlrp3-inflammasome-by-particles-and-crystals-a-continuing-challenge-of-immunology-and-toxicology
#15
REVIEW
Qiang Ma, Chol Seung Lim
Particles and crystals constitute a unique class of toxic agents that humans are constantly exposed to both endogenously and from the environment. Deposition of particulates in the body is associated with a range of diseases and toxicity. The mechanism by which particulates cause disease remains poorly understood due to the lack of mechanistic insights into particle-biological interactions. Recent research has revealed that many particles and crystals activate the NLRP3 inflammasome, an intracellular pattern-recognition receptor...
September 14, 2023: Annual Review of Pharmacology and Toxicology
https://read.qxmd.com/read/37683278/g-protein-coupled-receptor-signaling-new-insights-define-cellular-nanodomains
#16
REVIEW
Martin J Lohse, Andreas Bock, Manuela Zaccolo
G protein-coupled receptors are the largest and pharmacologically most important receptor family and are involved in the regulation of most cell functions. Most of them reside exclusively at the cell surface, from where they signal via heterotrimeric G proteins to control the production of second messengers such as cAMP and IP3 as well as the activity of several ion channels. However, they may also internalize upon agonist stimulation or constitutively reside in various intracellular locations. Recent evidence indicates that their function differs depending on their precise cellular localization...
September 8, 2023: Annual Review of Pharmacology and Toxicology
https://read.qxmd.com/read/37585662/circulating-biomarkers-instead-of-genotyping-to-establish-metabolizer-phenotypes
#17
REVIEW
Roman Tremmel, Ute Hofmann, Mathias Haag, Elke Schaeffeler, Matthias Schwab
Pharmacogenomics (PGx) enables personalized treatment for the prediction of drug response and to avoid adverse drug reactions. Currently, PGx mainly relies on the genetic information of absorption, distribution, metabolism, and excretion (ADME) targets such as drug-metabolizing enzymes or transporters to predict differences in the patient's phenotype. However, there is evidence that the phenotype-genotype concordance is limited. Thus, we discuss different phenotyping strategies using exogenous xenobiotics (e...
August 16, 2023: Annual Review of Pharmacology and Toxicology
https://read.qxmd.com/read/37585660/from-thalidomide-to-rational-molecular-glue-design-for-targeted-protein-degradation
#18
REVIEW
Vladas Oleinikovas, Pablo Gainza, Thomas Ryckmans, Bernhard Fasching, Nicolas H Thomä
Thalidomide and its derivatives are powerful cancer therapeutics that are among the best-understood molecular glue degraders (MGDs). These drugs selectively reprogram the E3 ubiquitin ligase cereblon (CRBN) to commit target proteins for degradation by the ubiquitin-proteasome system. MGDs create novel recognition interfaces on the surface of the E3 ligase that engage in induced protein-protein interactions with neosubstrates. Molecular insight into their mechanism of action opens exciting opportunities to engage a plethora of targets through a specific recognition motif, the G-loop...
August 16, 2023: Annual Review of Pharmacology and Toxicology
https://read.qxmd.com/read/37585659/apathy-and-motivation-biological-basis-and-drug-treatment
#19
REVIEW
Harry Costello, Masud Husain, Jonathan P Roiser
Apathy is a disabling syndrome associated with poor functional outcomes that is common across a broad range of neurological and psychiatric conditions. Currently, there are no established therapies specifically for the condition, and safe and effective treatments are urgently needed. Advances in the understanding of motivation and goal-directed behavior in humans and animals have shed light on the cognitive and neurobiological mechanisms contributing to apathy, providing an important foundation for the development of new treatments...
August 16, 2023: Annual Review of Pharmacology and Toxicology
https://read.qxmd.com/read/37585658/targeting-efferocytosis-in-inflammaging
#20
REVIEW
Ivan K H Poon, Kodi S Ravichandran
Rapid removal of apoptotic cells by phagocytes, a process known as efferocytosis, is key for the maintenance of tissue homeostasis, the resolution of inflammation, and tissue repair. However, impaired efferocytosis can result in the accumulation of apoptotic cells, subsequently triggering sterile inflammation through the release of endogenous factors such as DNA and nuclear proteins from membrane permeabilized dying cells. Here, we review the molecular basis of the three key phases of efferocytosis, that is, the detection, uptake, and degradation of apoptotic materials by phagocytes...
August 16, 2023: Annual Review of Pharmacology and Toxicology
journal
journal
26728
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.